<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02391480</url>
  </required_header>
  <id_info>
    <org_study_id>M14-546</org_study_id>
    <nct_id>NCT02391480</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer</brief_title>
  <official_title>A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, first-in-human, dose escalation study in participants with advanced solid
      tumors to determine the pharmacokinetics, maximum tolerated dose and the recommended Phase 2
      dose of ABBV-075 at different monotherapy dosing schedules. In addition the study will
      evaluate the safety. tolerability and the pharmacokinetics of ABBV-075 monotherapy or
      combination therapy in disease specific expansion cohorts.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 14, 2015</start_date>
  <completion_date type="Actual">July 5, 2019</completion_date>
  <primary_completion_date type="Actual">July 5, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose of ABBV-075</measure>
    <time_frame>Minimum first cycle of dosing (28 days) up to one year for dose escalation segment.</time_frame>
    <description>Maximum tolerated dose is defined as the highest dose level at which less than 2 of 6 participants experience the same dose limiting toxicity. If more than 2 participants experience a different dose limiting toxicity, the maximum tolerated dose may be further evaluated or determined to be exceeded based on discussions with the investigators and medical monitors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (peak time, Tmax) for ABBV-075</measure>
    <time_frame>Approximately 24 hours following a single dose of ABBV-075 up to approximately 2 years.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Screening, Cycle 1 Day 1, 8 and 15, then Day 1 of each cycle up to approximately 2 years.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of ABBV-075</measure>
    <time_frame>Approximately 24 hours following a single dose of ABBV-075 up to approximately 2 years.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC)</measure>
    <time_frame>Cycle 1 Day 1 Pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post ABBV-075 dosing, and on Cycle 1 Day 15 at 14, 17, 20 hours post dose.</time_frame>
    <description>Area under the plasma concentration versus time curve from time 0 (pre-dose) to the time of the last measurable concentration (AUC 0-t).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of overall response (DOR)</measure>
    <time_frame>At screening, every 8 weeks from Cycle 1 Day 1, and at the Final visit up to approximately 2 years.</time_frame>
    <description>DOR is defined as the time from the participant's initial CR or PR to the time of disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>At screening, every 8 weeks from Cycle 1 Day 1, and at the Final visit up to approximately 2 years.</time_frame>
    <description>ORR is defined as the proportion of participants who have a complete response (CR) or partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Screening, every 8 weeks from Cycle 1 Day 1, and at the Final visit up to approximately 2 years.</time_frame>
    <description>PFS is defined as the time from the first dose of ABBV-075 to either disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Prostate Cancer</condition>
  <condition>Small Cell Lung Cancer</condition>
  <condition>Non-Hodgkins Lymphoma</condition>
  <arm_group>
    <arm_group_label>ABBV-075</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation cohorts of ABBV-075 monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABBV-075 and venetoclax combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion cohorts of ABBV-075 and venetoclax combination therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABBV-075 expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion cohorts of ABBV-075 monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-075</intervention_name>
    <description>ABBV-075 Oral tablets</description>
    <arm_group_label>ABBV-075</arm_group_label>
    <arm_group_label>ABBV-075 and venetoclax combination</arm_group_label>
    <arm_group_label>ABBV-075 expansion</arm_group_label>
    <other_name>Mivebresib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Venetoclax tablets, film-coated</description>
    <arm_group_label>ABBV-075 and venetoclax combination</arm_group_label>
    <other_name>Venclexta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participant in the dose escalation cohorts must have histological confirmation of
             locally advanced or metastatic solid tumor that is either refractory after standard of
             care therapy for the disease or for which standard of care therapy or does not exist.

          2. Participants in the expansion cohorts must have histological confirmation of AML,
             Multiple Myeloma, breast cancer, NSCLC, prostate cancer, SCLC, or NHL that is either
             refractory after standard of care therapy or for which standard of care therapy does
             not exist.

          3. Participant must have an Eastern Cooperative Oncology Group (ECOG) Performance status
             of: 0 - 1 (dose escalation cohorts) or 0 - 2 (expansion cohorts)

          4. Participants in the dose escalation cohort must have a serum albumin of â‰¥ 3.2 g/dL at
             screening.

          5. Adequate bone marrow, renal, and hepatic function.

          6. QTc interval &lt; 480 milliseconds (msec) on the baseline electrocardiogram.

        Exclusion Criteria:

          1. Participant has untreated brain or meningeal metastases.

          2. Participant has received anti-cancer therapy including chemotherapy, immunotherapy,
             biologic or any investigational therapy within a period of 21 days prior to Study Day
             1.

          3. Participant has active peptic ulcer disease or other hemorrhagic
             esophagitis/gastritis.

          4. Symptoms of gross hematuria or gross hemoptysis.

          5. Exhibits symptomatic or persistent, uncontrolled hypertension (BP &gt; or = to 140 and/or
             diastolic pressure of &gt; or = to 90 mm Hg).

          6. History of long QT syndrome.

          7. Peripheral neuropathy greater than or equal to grade 2.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scottsdale Healthcare /ID# 132963</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258-4566</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope /ID# 154053</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Comp Cancer Ctr /ID# 154644</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University /ID# 136982</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago /ID# 155453</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1443</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univ School Medicine /ID# 132946</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Univ Med Ctr /ID# 154647</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research /ID# 154059</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ TX, MD Anderson /ID# 132276</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center /ID# 164122</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Piha-Paul SA, Sachdev JC, Barve M, LoRusso P, Szmulewitz R, Patel SP, Lara PN Jr, Chen X, Hu B, Freise KJ, Modi D, Sood A, Hutti JE, Wolff J, O'Neil BH. First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors. Clin Cancer Res. 2019 Nov 1;25(21):6309-6319. doi: 10.1158/1078-0432.CCR-19-0578. Epub 2019 Aug 16.</citation>
    <PMID>31420359</PMID>
  </results_reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 12, 2015</study_first_submitted>
  <study_first_submitted_qc>March 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2015</study_first_posted>
  <last_update_submitted>November 27, 2019</last_update_submitted>
  <last_update_submitted_qc>November 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Bromodomain Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

